文献速递腹部CT

胰腺癌新辅助治疗后CT肿瘤可切除性与治疗反应评估:观察者间一致性研究

Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
PubMed 文献 · Eur Radiol · 2022-01-15

回顾性纳入2017至2020年77例接受新辅助治疗的临界可切除胰腺癌患者,6名阅片者独立评估初诊与再分期CT。肿瘤可切除性三分类的观察者间一致性为0.64,可切除或临界可切除与不可切除二分类一致性为0.84,肿瘤反应分级一致性为0.89。仅以「可切除」为阳性预测阴性切缘的汇总敏感度48%、特异度61%;以「可切除」或「临界可切除」为阳性时敏感度91%、特异度5%。

要点

  • 再分期CT区分可切除或临界可切除与不可切除癌的一致性高(Gwet系数0.84),可用于筛选手术候选者。
  • 三分类可切除性(可切除/临界可切除/不可切除)的一致性为0.64(95%CI 0.56-0.71)。
  • 以「可切除」或「临界可切除」为阳性预测阴性切缘时敏感度91%但特异度仅5%。

核心结论

  • 新辅助治疗后胰腺癌再分期CT在筛选手术候选者方面具有高观察者间一致性,可可靠用于临床。

研究设计与样本

  • 回顾性研究,纳入2017至2020年接受新辅助治疗的临界可切除胰腺癌患者77例,中位年龄66岁(59-70),6名阅片者独立评估初诊与再分期CT,以NCCN指南分类可切除性,并按作者提出的5级分级标准评估肿瘤反应。

诊断标准与关键数值

  • 可切除性三分类(可切除/临界可切除/不可切除)的观察者间一致性Gwet系数0.64(95%CI 0.56-0.71)。
  • 可切除或临界可切除与不可切除二分类的观察者间一致性Gwet系数0.84(95%CI 0.77-0.91)。
  • 肿瘤反应5级分级的观察者间一致性Gwet系数0.89(95%CI 0.85-0.92)。
  • 仅以再分期CT「可切除」为阳性预测阴性切缘,汇总敏感度48%(95%CI 43-52%),特异度61%(95%CI 57-64%)。
  • 以再分期CT「可切除」或「临界可切除」为阳性预测阴性切缘,汇总敏感度91%(95%CI 89-94%),特异度5%(95%CI 4-6%)。

临床应用与阅片要点

  • 再分期CT区分可切除或临界可切除与不可切除癌的一致性高(Gwet系数0.84),可可靠用于新辅助治疗后手术候选者的筛选。
  • 以「可切除」或「临界可切除」为阳性预测阴性切缘时敏感度91%但特异度仅5%,阅片报告需注意该标准的低特异度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: First, to measure inter-observer agreement regarding tumor resectability and response, and second, to measure diagnostic performance in predicting negative resection margin, on re-staging CTs of patients who received neoadjuvant therapy for pancreatic cancer.

METHODS: This retrospective study included patients who received neoadjuvant therapy for borderline resectable pancreatic cancer from 2017 to 2020. Six readers independently evaluated initial staging and re-staging CT images. They categorized the resectability on re-staging CT based on the NCCN guideline, and evaluated tumor response to neoadjuvant therapy according to our proposed criteria on a 5-grade scale. For inter-observer agreement, Gwet's agreement coefficients were used. A crossed random effect model was used to pool the sensitivity and specificity of six readers in predicting negative resection margin.

RESULTS: Seventy-seven patients with the median age of 66 (59-70) were included. The pooled agreement for tumor resectability was 0.64 (95% CI, 0.56-0.71) for differentiating the three categories, and 0.84 (0.77-0.91) for differentiating resectable or borderline resectable cancer vs. unresectable cancer. Agreement for tumor response grade was 0.89 (0.85-0.92). The pooled sensitivity and specificity for predicting negative resection margin were 48% (43-52%) and 61% (57-64%), respectively, when only "resectable" on re-staging CT was considered as index test positive. When either "resectable"' or "borderline resectable" was considered as positive, the pooled sensitivity and specificity were 91% (89-94%) and 5% (4-6%), respectively.

CONCLUSION: CT can be used reliably with a high inter-observer agreement in selecting candidates for surgery after neoadjuvant therapy of pancreatic cancer.

KEY POINTS: • On CT following neoadjuvant therapy of pancreatic cancer, six readers showed high agreement in differentiating resectable or borderline resectable vs. unresectable cancer (Gwet's coefficient, 0.84). • Inter-observer agreement was also high for our proposed tumor response grade (Gwet's coefficient, 0.89). • Specificity was very low (5%) while sensitivity was high (91%) when either resectable or borderline resectable cancer on re-staging CT was considered as predictive of negative resection margin status.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim, Lee, Chang, et al. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study. Eur Radiol. 2022. PMID: 35032213. doi:10.1007/s00330-021-08494-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。